NanoLogix Begins Construction of Production Facility for Medical Test Kits
21 April 2009 - 11:45PM
PR Newswire (US)
HUBBARD, Ohio, April 21 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(OTC: NNLX) -- NanoLogix Inc. has begun construction on a 2,800
square foot manufacturing facility at its headquarters in Hubbard,
Ohio. It will contain a production cleanroom, cold-storage vault,
and shipping and receiving area to be used in the fabrication of
BNP(TM) Ultra-Fast test kits. The revolutionary new BNP(TM) kits
provide accelerated detection of bacteria and pathogens -- 100 to
600% faster than conventional Petri plate testing. They will have
broad applications in Homeland Security, human and veterinary
medicine, processing and safety of food, cosmetics and drugs,
research and development, and industrial and environmental testing.
One of the foremost bio-defense and biomedical research centers in
the U.S. recently found in its tests that the BNP(TM) provided
results up to four times faster than current Petri plate methods.
Using the BNP(TM) they were able to view anthrax cultures in
one-quarter of the time, and bubonic plague (Black Death) cultures
in half of the time possible with the best traditional methods. The
study appears in the current online issue of Letters in Applied
Microbiology. Link to study:
http://nanologix.com/downloads/NNLX_resource_3.pdf The new facility
will replace the company's current limited-production operation at
its research and development laboratory in Cincinnati, boosting
production capability to thousands of BNP(TM) kits per day. This
provides the opportunity for expanded R&D of other NanoLogix
products at the Cincinnati lab. The BNP(TM) kit is based on
NanoLogix's revolutionary sandwiched-membrane Petri technology. The
company believes the BNP(TM) has a high potential of capturing a
significant percentage of the annual multi-billion dollar Petri
plate market in both the United States and internationally.
NanoLogix CEO Bret Barnhizer stated: "With the BNP(TM) kits, we
believe we are on our way to establishing a new 'gold Standard' for
microorganism detection that will have a revolutionary effect on
medical testing, diagnosis and treatment. This production facility
will enable us to capitalize on our technology and provide product
to those who are rapidly becoming aware of the BNP(TM) potential".
The test kits provide users the ability for faster detection of a
long list of pathogens, including E-coli, Salmonella, Listeria,
Enterobacter, Staphylococcus, Anthrax and Bubonic plague. In
addition to providing ultra-fast viewing of microorganisms normally
cultured on standard Petri plates, the BNP(TM) kits can be used to
assist in early detection of some of the most dangerous pathogens
in the world, including those that pose significant potential
threats for use as bio-weapons by terrorists. The BNP(TM)
production operation is expected to create a dozen jobs in the
economically depressed Youngstown, Ohio, area, with more to follow
as product demand increases. Other NNLX News: NanoLogix recently
received a substantial royalty payment for 2008 from NutraPharma, a
bio-pharmaceutical company with a license on a number of NanoLogix
patents. CEO Bret Barnhizer and Director John Chatterton recently
met with U.S. Representative Tim Ryan (Ohio 17th District) in
Washington DC for a discussion of Federal programs related to
business assistance. About NanoLogix, Inc. NanoLogix is a
biotechnology company focused primarily on medical diagnostics. Its
products offer accelerated detection and identification of
microorganisms present in infectious and non-infectious human
diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer,
cystic fibrosis, anthrax, and plague. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and
bioreactor-based hydrogen generation. More information on NanoLogix
is available at: http://www.nanologix.com/ This press release
contains statements, which may constitute "forward- looking
statements" within the meaning of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: NanoLogix, Inc. Investor Relations Carol Surrena
Telephone: 330-534-0800 E-mail: DATASOURCE: NanoLogix, Inc.
CONTACT: Carol Surrena, Investor Relations of NanoLogix, Inc.,
+1-330-534-0800, Web Site: http://www.nanologix.com/
Copyright